Trends in Dual Antiplatelet Therapy of Aspirin and Clopidogrel and Outcomes in Ischemic Stroke Patients Noneligible for POINT/CHANCE Trial Treatment
Journal of the American Heart Association · 21.05.2024 · 13 (10)
DOI: 10.1161/jaha.123.033611 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 21.05.2024. Verfasst von Joon-Tae Kim und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Chonnam National University Hospital Chonnam National University Medical School Gwangju Korea. Hauptthemen laut MEDLINE: Clopidogrel, Aspirin, Ischemic Stroke, Dual Anti-Platelet Therapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaganfall
Abstract (Originalsprache)
Background Recent clinical trials established the benefit of dual antiplatelet therapy with aspirin and clopidogrel (DAPT‐AC) in early‐presenting patients with minor ischemic stroke. However, the impact of these trials over time on the use and outcomes of DAPT‐AC among the patients with nonminor or late‐presenting stroke who do not meet the eligibility criteria of these trials has not been delineated. Methods and Results In a multicenter stroke registry, this study examined yearly changes from April 2008 to August 2022 in DAPT‐AC use for stroke patients ineligible for CHANCE/POINT (Clopidogrel in High‐Risk Patients with Acute Nondisabling Cerebrovascular Events/Platelet‐Oriented Inhibition in New TIA and Minor Ischemic Stroke) clinical trials due to National Institutes of Health Stroke Scale >4 or late arrival beyond 24 hours of onset. A total of 32 118 patients (age, 68.1±13.1 years; male, 58.5%) with National Institutes of Health Stroke Scale of 4 (interquartile range, 1–7) were analyzed. In 2008, DAPT‐AC was used in 33.0%, other antiplatelets in 62.7%, and no antiplatelet in 4.3%. The frequency of DAPT‐AC was relatively unchanged through 2013, when the CHANCE trial was published, and then increased steadily, reaching 78% in 2022, while other antiplatelets decreased to 17.8% in 2022 ( P trend
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Chonnam National University Hospital Chonnam National University Medical School Gwangju Korea.
- Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center University of Ulsan College of Medicine Seoul Korea.
- Department of Neurology, Cerebrovascular Center Seoul National University Bundang Hospital Seongnam Korea.
- Department of Neurology Korea University Guro Hospital Seoul Korea.
- Department of Neurology, Uijeongbu Eulji Medical Center Eulji University School of Medicine Uijeongbu-si Korea.
- Department of Neurology, Nowon Eulji Medical Center Eulji University School of Medicine Seoul Korea.
ORCID-Profile: Joon-Tae Kim, Ji Sung Lee, Hyunsoo Kim, Beom Joon Kim, Keon-Joo Lee, Kyusik Kang, Soo Joo Lee, Jae Guk Kim, Jae-Kwan Cha, Dae-Hyun Kim, Tai Hwan Park, Kyungbok Lee, Jun Lee, Keun-Sik Hong, Yong-Jin Cho, Hong-Kyun Park, Byung-Chul Lee, Kyung-Ho Yu, Mi Sun Oh, Jay Chol Choi, Jee-Hyun Kwon, Wook-Joo Kim, Dong-Ick Shin, Kyu Sun Yum, Sung Il Sohn, Jeong-Ho Hong, Man-Seok Park, Wi-Sun Ryu, Kwang-Yeol Park, Juneyoung Lee, Jeffrey L Saver, Hee-Joon Bae
Zitieren
APA
Kim, J. T., Lee, J. S., Kim, H., Kim, B. J., Lee, K. J., Park, J. M., Kang, K., Lee, S. J., Kim, J. G., Cha, J. K., Kim, D. H., Park, T. H., Lee, K., Lee, J., Hong, K. S., Cho, Y. J., Park, H. K., Lee, B. C., Yu, K. H., …, & Bae, H. J. (2024). Trends in Dual Antiplatelet Therapy of Aspirin and Clopidogrel and Outcomes in Ischemic Stroke Patients Noneligible for POINT/CHANCE Trial Treatment. Journal of the American Heart Association, 13(10). https://doi.org/10.1161/jaha.123.033611
Vancouver
Kim JT, Lee JS, Kim H, Kim BJ, Lee KJ, Park JM, et al. Trends in Dual Antiplatelet Therapy of Aspirin and Clopidogrel and Outcomes in Ischemic Stroke Patients Noneligible for POINT/CHANCE Trial Treatment. Journal of the American Heart Association. 2024;13(10). doi:10.1161/jaha.123.033611
BibTeX
@article{Kim2024,
author = {Kim, Joon-Tae and Lee, Ji Sung and Kim, Hyunsoo and Kim, Beom Joon and Lee, Keon-Joo and Park, Jong-Moo and Kang, Kyusik and Lee, Soo Joo and Kim, Jae Guk and Cha, Jae-Kwan and Kim, Dae-Hyun and Park, Tai Hwan and Lee, Kyungbok and Lee, Jun and Hong, Keun-Sik and Cho, Yong-Jin and Park, Hong-Kyun and Lee, Byung-Chul and Yu, Kyung-Ho and Oh, Mi Sun and Kim, Dong-Eog and Choi, Jay Chol and Kwon, Jee-Hyun and Kim, Wook-Joo and Shin, Dong-Ick and Yum, Kyu Sun and Sohn, Sung Il and Hong, Jeong-Ho and Lee, Sang-Hwa and Park, Man-Seok and Ryu, Wi-Sun and Park, Kwang-Yeol and Lee, Juneyoung and Saver, Jeffrey L and Bae, Hee-Joon},
title = {Trends in Dual Antiplatelet Therapy of Aspirin and Clopidogrel and Outcomes in Ischemic Stroke Patients Noneligible for POINT/CHANCE Trial Treatment},
journal = {Journal of the American Heart Association},
year = {2024},
volume = {13},
number = {10},
doi = {10.1161/jaha.123.033611}
}
EUVIMED